2018 Participants

Home » 2018 Participants

Discover who attended BioFIT 2018

2018 Sponsors

Gold Sponsor

Globe Linkedin Twitter Facebook Instagram

Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Sanofi’s presentation “Why partner with Sanofi?”
Speaker: Murielle Gitton, Head R&D Transactions
Tuesday, November 29th | 3.15 – 3.30 pm | Innov’Area

Silver Sponsor

Globe Linkedin Twitter Facebook Instagram

Ferring

Ferring Pharmaceuticals is a privately owned research-driven, specialty biopharmaceutical company committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring employs 6,500 people worldwide with operating subsidiaries in 65 countries and markets its products in 110 countries. Ferring is actively looking for new opportunities, new partners to develop new innovative treatment solutions for patients.

Bronze Sponsors

Globe Linkedin Twitter Facebook Instagram

Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Globe Linkedin Twitter Facebook Instagram

Boehringer Ingelheim

As an independent company active in both human and animal health, Boehringer Ingelheim has learned over generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action. Decades of cutting-edge science and innovation has enabled us to deliver many pioneering breakthroughs in some of the most devastating diseases and challenging areas we face globally. Continuing this journey hinges on collaboration.

We believe that working together with our global community of partners brings critical diversity to innovation and accelerates the next breakthroughs in human and animal health that will transform lives now and in generations to come. This collective power, in the tireless pursuit of science and solutions, enables us to build together a healthier, more sustainable, and equitable tomorrow.

Globe Linkedin Twitter Facebook Instagram

GENFIT

GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development. Other assets target other life-threatening disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA).

Globe Linkedin Twitter Facebook Instagram

MSD

MSD’s success stems from translating research into life-saving medical breakthroughs. From our development of the first measles and mumps vaccines to treatments for cancer and diabetes, we’ve become an industry leader in bringing innovative new medicines to patients. Approximately half of our pipeline is attributable to acquisitions, alliance partnerships and patents with our team executing 76 significant business development transactions in 2023. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life. Learn more at www.merck.com/licensing.

Globe Linkedin Twitter Facebook Instagram

Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us.

Globe Linkedin Twitter Facebook Instagram

Roche

Roche is a leading healthcare company and is heavily investing into R&D, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the CNS. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare. Our Pharma Partnering team provides comprehensive BD and alliance management support for Roche and Genentech’s R&D units and the broader pharmaceutical division. Alongside the broad internal pipeline, external innovation has always been a critical component of our R&D strategy.

Globe Linkedin Twitter Facebook Instagram

VIB

VIB is a life sciences research institute, based in Flanders, Belgium. Some 1,500 top VIB scientists conduct pioneering basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications. These applications are often developed by young start-ups from VIB or through collaborations with other companies. This leads to additional employment and bridges the gap between scientific research and entrepreneurship.

Contributing Sponsors

Globe Linkedin Twitter Facebook Instagram

EBD Group

EBD Group specializes in bringing people together, whether face-to-face at one of our leading global life science partnering events powered by partneringONE, or virtually through our online community of dealmakers and thought leaders.

Globe Linkedin Twitter Facebook Instagram

LFB

The LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare in three major fields of therapy: immunology, haemostasis and intensive care. The LFB group is today a European key player in the field of therapeutic proteins. Over 2,000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients.